Trial Profile
A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) Inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) Inhibitor AT7519M in Patients With Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs AT 7519 (Primary) ; Onalespib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Endometrial cancer; Fibroma; Gastrointestinal stromal tumours; Head and neck cancer; Mouth neoplasm; Non-small cell lung cancer; Oropharyngeal cancer; Ovarian cancer; Salivary gland cancer; Sarcoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- 13 Nov 2020 Status changed from completed to active, no longer recruiting.
- 18 Sep 2020 Status changed from active, no longer recruiting to completed.
- 25 Jul 2020 Planned primary completion date changed from 30 Jun 2020 to 1 Sep 2020.